Financial Contrast: Black Titan (BTTC) vs. Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its rivals? We will compare Black Titan to related businesses based on the strength of its dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Insider and Institutional Ownership

57.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by insiders. Comparatively, 20.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.08%	-912.69%	-63.05%

Earnings and Valuation

This table compares Black Titan and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.58
Black Titan Competitors	$222.38 million	-$53.25 million	-11.65

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Black Titan and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	197	218	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 120.15%. Given Black Titan’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its rivals.

Risk and Volatility

Black Titan has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.68, indicating that their average share price is 32% less volatile than the S&P 500.

Summary

Black Titan rivals beat Black Titan on 7 of the 12 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.